You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 277 No. 16, April 23, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Hypercholesterolemia in Women

Equality, Effectiveness, and Extrapolation of Evidence

Thomas A. Pearson, MD, PhD; Merle Myerson, MD, EdD

JAMA. 1997;277(16):1320-1321.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The well-established fact that male sex is a risk factor for coronary heart disease (CHD) has been interpreted by some clinicians that CHD risk is lower for all women, that risk factors for CHD morbidity and mortality are somehow less predictive in women than in men, and that interventions to reduce that risk of CHD are inherently less effective in women. In this issue of THE JOURNAL, Schrott et al1 describe the extent to which lipid abnormalities are treated in women, identifying those factors that are associated with achieving (or not achieving) goals in low-density lipoprotein (LDL) cholesterol levels as set forth by the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) guidelines. In 2763 postmenopausal women with documented CHD recruited into a clinical trial of estrogen replacement therapy, 91% did not meet the NCEP ATP-II goals of an LDL cholesterol level of 2.6 mmol/L (100 mg/dL) or . . . [Full Text PDF of this Article]


Author Affiliations

From the Mary Imogene Bassett Research Institute, Cooperstown, NY (Drs Pearson and Myerson), and the Departments of Public Health and Medicine, Columbia University, New York, NY (Dr Pearson). Dr Pearson is now with the Department of Community and Preventive medicine, University of Rochester School of Medicine, Rochester, NY.


Footnotes

Reprints: Thomas A. Pearson, MD, PhD, Department of Community and Preventive Medicine, University of Rochester School of Medicine, 601 Elmwood Ave, Rochester, NY 14642 (e-mail: tpearson@prevmed.rochester.edu).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.